Action
HER2
Approval Jurisdiction
2020 FDA
Approved for clinical use
MHER2-positive breast cancer
CAS
1350624-75-7
Commercial Vendor
Raven Biotech
Compound Image
Margetuximab.png
Compound name
Margetuximab
Reference
Reference 2
Approved Drug List
1